Preclinical pharmacokinetics/pharmacodynamics studies defining the role of ethambutol in Mycobacterium kansasii lung disease.

Rifampin, isoniazid, and ethambutol are the backbone of the regimen used to treat Mycobacterium kansasii-complex (MKC) lung disease. However, ethambutol pharmacokinetics/pharmacodynamics (PK/PD) studies to inform on optimal exposure target and clinic…

Preview only. Read the full abstract at the source